Recurrent glioblastoma (GBM) or High-Grade Glioma (HGG) remains one of the most challenging neuro-oncological conditions, with limited survival benefit from conventional therapies. Emerging molecularly targeted approaches, particularly Lutetium-177–based peptide receptor radionuclide therapy (PRRT), are showing promise as innovative strategies for select…
